MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ
23.29
-0.46
-1.94%
After Hours: 23.18 -0.11 -0.47% 16:03 05/29 EDT
OPEN
23.36
PREV CLOSE
23.75
HIGH
23.63
LOW
23.14
VOLUME
2.08M
TURNOVER
0
52 WEEK HIGH
33.71
52 WEEK LOW
22.01
MARKET CAP
3.94B
P/E (TTM)
9.20
1D
5D
1M
3M
1Y
5Y
Alkermes to Present Promising Narcolepsy Treatment Data at Annual Sleep Conference
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024. The company's novel treatment for narcolepsy is in development as a once-daily treatment for the condition. Data from the full cohort of patients in a clinical study will be presented. Findings from in-depth qualitative interviews on the burden of nar colepsy will also be presented at the meeting.
Benzinga · 1d ago
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
NASDAQ · 2d ago
Weekly Report: what happened at ALKS last week (0520-0524)?
Weekly Report · 2d ago
6 Analysts Assess Alkermes: What You Need To Know
Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months. Alkermes is a biotechnology company that develops and commercializes pharmaceutical products. The company's revenue growth over the past three months has been noteworthy. The stock has a 12-month average price target of $.
Benzinga · 6d ago
Alkermes Price Target Raised to $48.00/Share From $43.00 by Cantor Fitzgerald
Dow Jones · 6d ago
Alkermes Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 6d ago
Weekly Report: what happened at ALKS last week (0513-0517)?
Weekly Report · 05/20 09:06
The Bottom Fishing Club: Alkermes Has Great Value And Safety
Seeking Alpha · 05/17 12:27
More
About ALKS
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Webull offers Alkermes Plc stock information, including NASDAQ: ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.